This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): KUR-1246, bedoradrine sulfate
Description: MN-221 is a highly-selective b2-adrenergic receptor agonist. MediciNova has developed an intravenous formulation of MN-221 that may effectively bypass the constricted airways in status asthmaticus to deliver effective concentrations of the drug to the lungs.
MediciNova and Kissei
In February 2004, MediciNova announced the acquisition of KUR-1246 from Kissei Pharmaceutical. The drug will be added to the MediciNova product pipeline under the acronym MN-221. Under the agreement, MediciNova obtains exclusive worldwide rights outside of Japan to MN221 in exchange for upfront, milestone, and royalty payments to Kissei. Financial terms of the agreement will not be disclosed.
In October 2011, MediciNova announced that Kissei will pay MediciNova $2.5 million, within 30 days, to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD)in the United States.
MediciNova and Zhejiang Medicine
In March 2011, MediciNova and Zhejiang Medicine announced the signing of a letter of intent for the formation of a Joint Venture Company to develop and commercialize MediciNova's MN-221 in China.
In June 2011, MediciNova and Zhejiang Medicine...See full deal structure in Biomedtracker
Partners: Kissei Pharmaceutical Co., Ltd Zhejiang Medicine Co., Ltd.
Additional information available to subscribers only: